Publication | Open Access

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

Metabolic SyndromeMedicinal ChemistryBiochemistryFunctional SelectivityMedicineNatural SciencesPharmacological AgentPharmacotherapyPharmacologyDrug DiscoveryGastrointestinal Peptide HormonePotential Treatment